Li, Christopher

Open Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer Coordinating 0 0
EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project Coordinating 0 0
EDRN Breast and Ovary Cancer CVC, Study 2: Phase 3 retrospective validation of ovarian cancer early detection markers in serial preclinical samples from the PLCO trial Leading 0 0
EDRN Breast and Ovary Cancer CVC, Study 3: Phase 3 Validation of screening decision rules in preclinical UKCTOCS serial samples Leading 0 0
EDRN Breast and Ovary Cancer CVC, Study 4: Phase 3 Validation of Ovarian Cancer Serum Markers in Preclinical WHI Samples Leading 0 0
Identification of biomarkers for ER+ breast cancer Leading 0 0
Phase 3 Validation of Biomarkers for the Early Detection of ER+ Breast Cancer Leading 0 0
Study 5: Phase 2 and 3 Validations of Putative Breast Cancer Early Detection Candidates Leading 0 0
Validation of Early Detection Ovarian Cancer Biomarkers (Team Project) Involved 149 0

Closed Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Benign Breast Disease Team Project Involved 25 1
Breast Reference Set Application: Chris Li-FHCRC (2013) Leading 10 0
Breast Reference Set Application: Chris Li-FHCRC (2015) Leading 10 0
DCIS Team Project Leading 6 1
Triple Negative Breast Cancer Team Project Involved 147 0


Publication NamePubMed IDJournal
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. 26319120 Breast Cancer Res Treat
Dermcidin expression is associated with disease progression and survival among breast cancer patients. 24562771 Breast Cancer Res Treat
Designing early detection programs for ovarian cancer. 22180403 Ann Oncol
Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study. 22903690 Breast Cancer Res Treat
Discovery of novel plasma proteins as biomarkers for the development of incisional hernias after midline incision in patients with colorectal cancer: The ColoCare study. 27745870 Surgery
Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? 27001493 Clin Chem
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. 22155417 Gynecol Oncol
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. 26343159 Gynecol Oncol
Immunity to placental malaria. III. Impairment of interleukin(IL)-12, not IL-18, and interferon-inducible protein-10 responses in the placental intervillous blood of human immunodeficiency virus/malaria-coinfected women. 11756993 J Infect Dis
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. 22750949 Cancer Prev Res (Phila)
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. 22962406 Cancer Epidemiol Biomarkers Prev
JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. 24764577 Cancer Immunol Res
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. 23248253 J Clin Oncol
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. 21917606 J Natl Cancer Inst
Protein and glycomic plasma markers for early detection of adenoma and colon cancer. 27821646 Gut
Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity. 27769113 J Proteome Res
Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. 30099328 Cancer Epidemiol


Discovery and Validation of Breast Cancer Early Detection Biomarkers
We are actively engaged in breast cancer early detection biomarker discovery and validation using multiple proteomic platforms. Our focus is on use of high quality, well annotated preclinical blood specimens.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Photograph of Li, Christopher
Fred Hutchinson Cancer Center
M.D., Ph.D.
Person ID
EDRN Title
EDRN Principal Investigator
To update contact information, please visit the Data Management and Coordinating Center .